Department of Internal Medicine, Division of Gastroenterology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):25-37.
Aim of this review is to summarize the studies carried out, with particular interest in those who dealt with otilonium bromide in treatment of IBS. Irritable bowel syndrome (IBS).
IBS is a frequent gastrointestinal disease, characterized by a combination of several symptoms including abdominal pain or discomfort, flatulence and problems related to bowel habits (constipation and/or diarrhea). It affects about 15% of the western population, with a negative impact on the quality of life and also on health care costs. Face to such important complexity and negative impact, therapeutic options are still very limited and most of the pharmacological compounds mostly validated for short term use, are only partially controlling symptoms. Among those, anti-spasmodics are commonly used in clinical settings. Despite a discrete literature in support of these drugs, systematic collections of clinical evidence to support the use of anti-spasmodics and in particular the use of otilonium bromide in course of IBS are scarce.
Otilonium bromide is a systemically poorly absorbed antispasmodic, which has shown clear efficacy compared to placebo, in controlling symptoms related to IBS. Otilonium bromide was effective also in comparison to other drugs, such as pinaverium bromide and mebeverine, with a favorable tolerability profile. Further studies are necessary to better define duration of treatment and maximum therapeutic dose.
本综述的目的是总结已开展的研究，特别关注那些涉及溴氧托品治疗 IBS 的研究。肠易激综合征（IBS）。
IBS 是一种常见的胃肠道疾病，其特征是多种症状的组合，包括腹痛或不适、腹胀以及与肠道习惯相关的问题（便秘和/或腹泻）。它影响约 15%的西方人口，对生活质量和医疗保健成本都有负面影响。面对如此重要的复杂性和负面影响，治疗选择仍然非常有限，大多数经过短期验证的药物化合物仅部分控制症状。其中，抗痉挛药在临床环境中常用。尽管有大量文献支持这些药物，但系统收集的临床证据支持抗痉挛药的使用，特别是在 IBS 过程中使用溴氧托品的证据很少。
溴氧托品是一种全身吸收不良的抗痉挛药，与安慰剂相比，在控制与 IBS 相关的症状方面显示出明显的疗效。溴氧托品与其他药物（如匹那韦溴化物和美贝维林）相比也有效，具有良好的耐受性。需要进一步研究以更好地确定治疗持续时间和最大治疗剂量。
